AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39049044 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessments of diabetes empowerment and diabetes-related distress
Number of subjects: 0
Study 39049042 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers investigated (neuropsychological tests: MMSE and delayed free recall, brain glucose metabolism)
Number of subjects: 500
Study 39049073 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (360 mg/day)
Number of subjects: 60
Study 39049073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 39049078 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes shared medical appointments (SMAs)
Number of subjects: 22
Study 39049078 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of additional resources for patients with diabetes
Number of subjects: 22
Study 39049078 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of an effective key person (implementation champion)
Number of subjects: 22
Study 39049078 — intervention group
Group type: EXPERIMENTAL
Intervention: Low or managed employee turnover, strong baseline practice culture, previous experience delivering SMAs
Number of subjects: 22
Study 39049087 — intervention group
Group type: EXPERIMENTAL
Intervention: Incretin effect measured as the difference between plasma insulin area under the curve during an oral glucose tolerance test (OGTT) and intravenous glucose infusion.
Number of subjects: 30
Study 39049087 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic controls (n=10)
Number of subjects: 30
Study 39049092 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity IMT
Number of subjects: 92
Study 39049092 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity IMT
Number of subjects: 92
Study 39049092 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed intensity IMT
Number of subjects: 92
Study 39049092 — intervention group
Group type: COMPARATOR
Intervention: Control (no IMT)
Number of subjects: 92
Study 39049121 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized intervention
Number of subjects: 255
Study 39049121 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized intervention
Number of subjects: 255
Study 39049121 — intervention group
Group type: COMPARATOR
Intervention: Usual Care Control (UCC)
Number of subjects: 255
Study 39049127 — intervention group
Group type: COMPARATOR
Intervention: Endovascular thrombectomy (EVT) within 6 hours (STAMINA-HERMES)
Number of subjects: 598
Study 39049127 — intervention group
Group type: COMPARATOR
Intervention: Endovascular thrombectomy (EVT) within 6-24 hours (STAMINA-AURORA)
Number of subjects: 598
Study 39049127 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy (EVT) outside RCT-criteria
Number of subjects: 598
Study 39049187 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-filtered infrared A radiation (WIRA) whole-body hyperthermia combined with immune checkpoint inhibitor (ICI) therapy (tislelizumab)
Number of subjects: 18
Study 39049618 — intervention group
Group type: EXPERIMENTAL
Intervention: Friction mechanics using elastomeric chain (160 g/side)
Number of subjects: 30
Study 39049618 — intervention group
Group type: COMPARATOR
Intervention: Frictionless mechanics using closing T-loops (0.017 × 0.025-inch TMA wire)
Number of subjects: 30
Study 39049802 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 15
Study 39049802 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment with saline infusion
Number of subjects: 15
Study 39049802 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment with exendin(9-39)NH2 infusion
Number of subjects: 15
Study 39049802 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 15
Study 39049803 — intervention group
Group type: EXPERIMENTAL
Intervention: TAMP-delivered gemcitabine
Number of subjects: 43
Study 39049803 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous chemoradiation
Number of subjects: 43
Study 39049803 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous systemic chemotherapy
Number of subjects: 43
Study 39049803 — intervention group
Group type: EXPERIMENTAL
Intervention: No prior treatment
Number of subjects: 43
Study 39049828 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma from BCG vaccinated patients
Number of subjects: 39
Study 39049828 — intervention group
Group type: COMPARATOR
Intervention: Plasma from placebo patients
Number of subjects: 39
Study 39050403 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised blood pressure management
Number of subjects: 328
Study 39050403 — intervention group
Group type: COMPARATOR
Intervention: Routine blood pressure management
Number of subjects: 328
Study 39050483 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI<25 kg/m²
Number of subjects: 118
Study 39050483 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI 25-40 kg/m²
Number of subjects: 118
Study 39050483 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI>40 kg/m²
Number of subjects: 118
Study 39050586 — intervention group
Group type: EXPERIMENTAL
Intervention: Dora R1 (autonomous telemedicine call)
Number of subjects: 202
Study 39050690 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive fall prevention model implemented in the community
Number of subjects: 11
Study 39050802 — intervention group
Group type: EXPERIMENTAL
Intervention: 150mg SHR6390 on Day 1; 600mg efavirenz orally at night from Day 8-26; 150mg SHR6390 on Day 22
Number of subjects: 20
Study 39050802 — intervention group
Group type: COMPARATOR
Intervention: 150mg SHR6390
Number of subjects: 20
Study 39050912 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D multiparametric ultrasound with computer-aided diagnosis (PCaVision)
Number of subjects: 438
Study 39050912 — intervention group
Group type: COMPARATOR
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 438
Study 39051019 — intervention group
Group type: EXPERIMENTAL
Intervention: Omidenepag isopropyl (OMDI) 0.002%
Number of subjects: 370
Study 39051019 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005%
Number of subjects: 370
Study 39051098 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing
Number of subjects: 45
Study 39051098 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive knee extension exercise testing
Number of subjects: 45
Study 39051104 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous exercise (≥6 metabolic equivalents for >60 hours per year)
Number of subjects: 1413
Study 39051104 — intervention group
Group type: COMPARATOR
Intervention: Nonvigorous exercise
Number of subjects: 1413
Study 39051647 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear-array endoscopic ultrasound (EUS)
Number of subjects: 79
Study 39051647 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 79
Study 39051647 — intervention group
Group type: COMPARATOR
Intervention: Combined use of EUS and NBI
Number of subjects: 79
Study 39051653 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hepatic arterial infusion chemotherapy (HAIC) with FOLFOX
Number of subjects: 470
Study 39051653 — intervention group
Group type: COMPARATOR
Intervention: Control cohort (no adjuvant HAIC)
Number of subjects: 470
Study 39051653 — intervention group
Group type: EXPERIMENTAL
Intervention: Training cohort (imaging-based model)
Number of subjects: 470
Study 39051653 — intervention group
Group type: COMPARATOR
Intervention: Control group (high-risk adjuvant HAIC)
Number of subjects: 470
Study 39052054 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-layer cone-beam CT 75 keV monoenergetic images
Number of subjects: 27
Study 39052070 — intervention group
Group type: EXPERIMENTAL
Intervention: Death Cafés for burnout prevention
Number of subjects: 0
Study 39052163 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Number of subjects: 187
Study 39052241 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adjustment group using Lexie B2 hearing aids
Number of subjects: 28
Study 39052241 — intervention group
Group type: COMPARATOR
Intervention: In situ audiometry group using Lexie B2 Plus hearing aids
Number of subjects: 28
Study 39052242 — intervention group
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa, 1200 mg, intravenously once every 2 weeks
Number of subjects: 146
Study 39052256 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab, 1200 mg intravenously, administered on day 1 of each 21-day cycle for four cycles, followed by chemoradiation therapy (CRT)
Number of subjects: 62
Study 39052256 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab, 1200 mg every 21 days continued for 1 year after CRT
Number of subjects: 62
Study 39052256 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab, 1200 mg, as part of the treatment regimen
Number of subjects: 62
Study 39052256 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab treatment
Number of subjects: 62
Study 39052289 — intervention group
Group type: EXPERIMENTAL
Intervention: Health system-embedded deprescribing intervention
Number of subjects: 2367
Study 39052289 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 2367
Study 39052328 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile Link intervention
Number of subjects: 0
Study 39052330 — intervention group
Group type: EXPERIMENTAL
Intervention: eMOTIVA app
Number of subjects: 300
Study 39052335 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based resilience-enhancing program (4 weeks)
Number of subjects: 96
Study 39052335 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 96
Study 39052473 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 39052647 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally appropriate text message boosters in Swahili coupled with a brief negotiational intervention (BNI) for alcohol use reduction.
Number of subjects: 0
Study 39052701 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotavirus vaccination (Rotarix)
Number of subjects: 184
Study 39052701 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated children
Number of subjects: 184
Study 39052716 — intervention group
Group type: EXPERIMENTAL
Intervention: RSM01, an investigational anti-RSV prefusion F monoclonal antibody (mAb); details on dosage and duration not available.
Number of subjects: 0
Study 39052715 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-day azithromycin treatment
Number of subjects: 0
Study 39052715 — intervention group
Group type: COMPARATOR
Intervention: Supportive treatment (control)
Number of subjects: 0
Study 39052718 — intervention group
Group type: EXPERIMENTAL
Intervention: NVX-CoV2515
Number of subjects: 829
Study 39052718 — intervention group
Group type: COMPARATOR
Intervention: NVX-CoV2373
Number of subjects: 829
Study 39052718 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent mixture
Number of subjects: 829
Study 39052726 — intervention group
Group type: EXPERIMENTAL
Intervention: RSVPreF3 OA vaccine
Number of subjects: 1653
Study 39052748 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabotegravir plus rilpivirine (CAB + RPV)
Number of subjects: 1245
Study 39052893 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear Implant (CI) surgery with audible ECochG monitoring
Number of subjects: 87
Study 39052893 — intervention group
Group type: COMPARATOR
Intervention: Cochlear Implant (CI) surgery without audible ECochG monitoring
Number of subjects: 87
Study 39053009 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based coaching (VBC)
Number of subjects: 28
Study 39053009 — intervention group
Group type: COMPARATOR
Intervention: Standard gynecology curriculum (control group)
Number of subjects: 28
Study 39053010 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-free DNA analysis for fetal antigen genotyping
Number of subjects: 156
Study 39053010 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell-free DNA analysis for antigens K1, E, C, Fy a, c, D(RhD)
Number of subjects: 156
Study 39053011 — intervention group
Group type: EXPERIMENTAL
Intervention: Panniculus retractor device
Number of subjects: 150
Study 39053011 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study 39053611 — intervention group
Group type: EXPERIMENTAL
Intervention: Deuruxolitinib 8 mg twice daily
Number of subjects: 0
Study 39053611 — intervention group
Group type: EXPERIMENTAL
Intervention: Deuruxolitinib 12 mg twice daily
Number of subjects: 0
Study 39053611 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39053653 — intervention group
Group type: EXPERIMENTAL
Intervention: Water exchange cap-assisted colonoscopy (WECAC)
Number of subjects: 280
Study 39053653 — intervention group
Group type: COMPARATOR
Intervention: Water exchange (WE)
Number of subjects: 280
Study 39053696 — intervention group
Group type: EXPERIMENTAL
Intervention: MNA <17
Number of subjects: 300
Study 39053696 — intervention group
Group type: EXPERIMENTAL
Intervention: MNA, SGA, SNAQ
Number of subjects: 300
Study 39053696 — intervention group
Group type: EXPERIMENTAL
Intervention: MNA
Number of subjects: 300
Study 39053696 — intervention group
Group type: EXPERIMENTAL
Intervention: SGA
Number of subjects: 300
Study 39053878 — intervention group
Group type: EXPERIMENTAL
Intervention: Short abutments (SA < 2 mm)
Number of subjects: 26
Study 39053878 — intervention group
Group type: COMPARATOR
Intervention: Long abutments (LA > 2 mm)
Number of subjects: 26
Study 39053878 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcrestal ≈2 mm implants with LA
Number of subjects: 26
Study 39053878 — intervention group
Group type: COMPARATOR
Intervention: Subcrestal ≈1 mm position with LA
Number of subjects: 26
Study 39053878 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcrestal implants
Number of subjects: 26
Study 39053924 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based firearm safety education
Number of subjects: 371
Study 39053924 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline survey about child safety behaviours)
Number of subjects: 371
Study 39053948 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg plus background csDMARD(s)
Number of subjects: 229
Study 39053954 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (200-500 mg daily)
Number of subjects: 1116
Study 39053954 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equivalent dose)
Number of subjects: 1116
Study 39053958 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran
Number of subjects: 92
Study 39053958 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid analysis framework
Number of subjects: 92
Study 39053957 — intervention group
Group type: EXPERIMENTAL
Intervention: BETTER Women programme with a trained peer health coach providing ongoing support after receipt of a BETTER prevention prescription.
Number of subjects: 408
Study 39053957 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (no intervention during the wait period).
Number of subjects: 408
Study 39053960 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg AMK injection on the first and fourth day of treatment
Number of subjects: 20
Study 39053961 — intervention group
Group type: EXPERIMENTAL
Intervention: Early pharmacotherapeutic treatment of clinically symptomatic and echocardiography-confirmed haemodynamically significant PDA
Number of subjects: 0
Study 39053961 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 39053972 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients living with frailty (CFS≥5)
Number of subjects: 1840
Study 39054302 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellular Bone Allograft (CBA; Trinity Elite)
Number of subjects: 252
Study 39054326 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive Training-Silver (MCT-Silver)
Number of subjects: 38
Study 39054374 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-month supervised exercise program
Number of subjects: 357
Study 39054374 — intervention group
Group type: COMPARATOR
Intervention: usual care (control group)
Number of subjects: 357
Study 39054420 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin-Angiotensin-System (RAS) blockers with beta-blockers and optionally spironolactone
Number of subjects: 252
Study 39054420 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 252
Study 39054420 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation (AF)
Number of subjects: 252
Study 39054420 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary heart disease
Number of subjects: 252
Study 39054420 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 252
Study 39054425 — intervention group
Group type: EXPERIMENTAL
Intervention: Costoclavicular lateral approach (Group CLB)
Number of subjects: 56
Study 39054425 — intervention group
Group type: EXPERIMENTAL
Intervention: Costoclavicular medial approach (Group CMB)
Number of subjects: 56
Study 39054425 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral sagittal technique (Group LSB)
Number of subjects: 56
Study 39054430 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus epacadostat
Number of subjects: 129
Study 39054430 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib/pazopanib
Number of subjects: 129
Study 39054460 — intervention group
Group type: EXPERIMENTAL
Intervention: Irreversible Electroporation (IRE) followed by reduced dose MR guided Radiation Therapy (MRgRT) with either 32.5 Gy in 5 Fractions or 22 Gy in 2 fractions
Number of subjects: 42
Study 39054462 — intervention group
Group type: EXPERIMENTAL
Intervention: E + P + C (epacadostat 100 mg BID + pembrolizumab 200 mg every 21 days + platinum-based chemotherapy)
Number of subjects: 178
Study 39054462 — intervention group
Group type: COMPARATOR
Intervention: PBO + P + C (placebo + pembrolizumab 200 mg every 21 days + platinum-based chemotherapy)
Number of subjects: 178
Study 39054462 — intervention group
Group type: EXPERIMENTAL
Intervention: E + P + C
Number of subjects: 178
Study 39054462 — intervention group
Group type: COMPARATOR
Intervention: PBO + P + C
Number of subjects: 178
Study 39054467 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus epacadostat
Number of subjects: 89
Study 39054467 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy
Number of subjects: 89
Study 39054467 — intervention group
Group type: COMPARATOR
Intervention: EXTREME regimen
Number of subjects: 89
Study 39054476 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 21 days plus oral epacadostat 100 mg twice daily (combination)
Number of subjects: 154
Study 39054476 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus pembrolizumab (control)
Number of subjects: 154
Study 39054476 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination group
Number of subjects: 154
Study 39054476 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 154
Study 39054479 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy (nCRT) with integrated multi-omics data (radiomics, gut microbiota, ctDNA)
Number of subjects: 0
Study 39054479 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant chemoradiotherapy (nCRT)
Number of subjects: 0
Study 39054485 — intervention group
Group type: EXPERIMENTAL
Intervention: Epacadostat 100 mg BID plus pembrolizumab
Number of subjects: 42
Study 39054485 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus pembrolizumab
Number of subjects: 42
Study 39054491 — intervention group
Group type: EXPERIMENTAL
Intervention: epacadostat plus pembrolizumab
Number of subjects: 93
Study 39054491 — intervention group
Group type: COMPARATOR
Intervention: placebo plus pembrolizumab
Number of subjects: 93
Study 39054496 — intervention group
Group type: EXPERIMENTAL
Intervention: Stakeholder insights on barriers and facilitators to healthy lifestyle behaviours
Number of subjects: 28
Study 39054496 — intervention group
Group type: EXPERIMENTAL
Intervention: School environment as a facilitator
Number of subjects: 28
Study 39054496 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaboration with community and governmental stakeholders
Number of subjects: 28
Study 39054511 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU survivors admitted after a cerebrovascular accident, intracerebral hemorrhage, or (neuro)trauma
Number of subjects: 3913
Study 39054511 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU survivors admitted due to respiratory disease
Number of subjects: 3913
Study 39054511 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU survivors admitted due to trauma
Number of subjects: 3913
Study 39054511 — intervention group
Group type: EXPERIMENTAL
Intervention: All studied 22 subgroups of ICU survivors
Number of subjects: 3913
Study 39054514 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise combined with Manual Therapy (MT)
Number of subjects: 0
Study 39054514 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise combined with Kinesiotaping (KT)
Number of subjects: 0
Study 39054514 — intervention group
Group type: COMPARATOR
Intervention: Core stability exercises
Number of subjects: 0
Study 39054514 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 0
Study 39054514 — intervention group
Group type: COMPARATOR
Intervention: Control-motor training
Number of subjects: 0
Study 39054596 — intervention group
Group type: EXPERIMENTAL
Intervention: Opium tincture
Number of subjects: 11
Study 39054596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 39054745 — intervention group
Group type: EXPERIMENTAL
Intervention: Community First Responders attending emergencies in rural areas
Number of subjects: 4500000
Study 39054745 — intervention group
Group type: EXPERIMENTAL
Intervention: Community First Responder falls response
Number of subjects: 4500000
Study 39054745 — intervention group
Group type: EXPERIMENTAL
Intervention: Community First Responders' involvement in high-priority emergency calls
Number of subjects: 4500000
Study 39054745 — intervention group
Group type: EXPERIMENTAL
Intervention: Community First Responders' impact on out-of-hospital cardiac arrest outcomes
Number of subjects: 4500000
Study 39054745 — intervention group
Group type: EXPERIMENTAL
Intervention: Community First Responders' training and support
Number of subjects: 4500000
Study 39054763 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise (EX) program, 3 days/week for 20 weeks
Number of subjects: 112
Study 39054763 — intervention group
Group type: COMPARATOR
Intervention: Treatment-As-Usual (TAU)
Number of subjects: 112